Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib

New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.

Detalles Bibliográficos
Autores principales: Alshiekh‐Nasany, Ruham, Zidan, Awss, Martinez, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134215/
https://www.ncbi.nlm.nih.gov/pubmed/27980759
http://dx.doi.org/10.1002/ccr3.729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134215/
https://www.ncbi.nlm.nih.gov/pubmed/27980759
http://dx.doi.org/10.1002/ccr3.729

Ejemplares similares